- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07727590
ER-VISION-AI Study (ER-VISION-AI)
21 juli 2026 bijgewerkt door: Ewha Womans University Mokdong Hospital
Multimodal Visual Language Model-Assisted Diagnostic Strategy in the Emergency Department: A Prospective Multicenter Randomized Controlled Trial (ER-VISION-AI Study)
Prospective, multicenter, randomized, open-label, blinded-endpoint (PROBE-like) clinical trial evaluating whether physician-supervised Generative Pre-trained Transformer (GPT)-assisted multimodal diagnostic support improves diagnostic concordance in emergency department patients presenting with acute cardiopulmonary symptoms.
Studie Overzicht
Toestand
Nog niet aan het werven
Studietype
Ingrijpend
Inschrijving (Geschat)
1000
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Yeji Kim, PhD
- Telefoonnummer: +82-10-2724-7740
- E-mail: lexie6169@gmail.com
Studie Locaties
-
-
-
Seoul, Zuid -Korea, 07804
- Ewha Womans University Mokdong Hospital
-
Contact:
- Yeji Kim, PhD
- Telefoonnummer: +82-10-2724-7740
- E-mail: lexie6169@gmail.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Age ≥18 years
- Presentation to a participating emergency department with acute cardiopulmonary symptoms, including chest pain, dyspnea, palpitations, syncope, dizziness, or fever accompanied by cardiopulmonary symptoms
- Performance of both a standard 12-lead electrocardiogram and chest radiography during the initial emergency department evaluation
- Availability of initial clinical assessment, vital signs, laboratory findings, and all mandatory clinical information required for the multimodal AI workflow
- Expected emergency department observation or hospital admission for at least 24 hours
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Inability or refusal to provide written informed consent
- Requirement for immediate life-saving intervention that precludes completion of the study workflow
- Death before completion of the initial emergency department diagnostic assessment
- Electrocardiographic quality insufficient for reliable physician or Artificial intelligence (AI) interpretation
- Chest radiographic quality insufficient for reliable physician or Artificial intelligence (AI) interpretation
- Cardiac pacing rhythm
- Missing mandatory clinical information required for the multimodal Artificial intelligence (AI) workflow
- Previous enrollment in the ER-VISION-AI trial
- Inability to establish a blinded adjudicated reference diagnosis
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: GPT-assisted multimodal visual language model (VLM) diagnostic strategy
Participants receive physician-supervised Generative Pre-trained Transformer (GPT)-assisted multimodal diagnostic support integrating electrocardiography, chest radiography, structured clinical information, laboratory findings, vital signs, and relevant medical history.
Treating physicians remain responsible for all diagnostic and therapeutic decisions.
|
A Generative Pre-trained Transformer (GPT)-based multimodal visual language model integrates electrocardiograms, chest radiographs, structured clinical information, laboratory findings, vital signs, and relevant clinical history to generate diagnostic suggestions and differential diagnoses for physician-supervised clinical decision support.
|
|
Actieve vergelijker: Conventional physician-guided diagnostic strategy
Participants undergo standard emergency department diagnostic evaluation according to routine clinical practice without Generative Pre-trained Transformer (GPT)-assisted diagnostic support.
|
Routine emergency department diagnostic evaluation performed according to standard clinical practice without AI-assisted diagnostic support.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnostic concordance between the final emergency department diagnosis and the blinded adjudicated reference diagnosis established at hospital discharge.
Tijdsspanne: During the index hospitalization, up to hospital discharge (average 3 days)
|
Diagnostic concordance between the treating physician's final emergency department diagnosis and the blinded adjudicated reference diagnosis based on the prespecified principal diagnostic category.
|
During the index hospitalization, up to hospital discharge (average 3 days)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnostic concordance after Generative Pre-trained Transformer (GPT)-assisted diagnostic support
Tijdsspanne: During the index emergency department visit (average 6 hours)
|
Diagnostic concordance between the physician's final emergency department diagnosis after Generative Pre-trained Transformer (GPT)-assisted multimodal diagnostic support and the blinded adjudicated reference diagnosis in participants assigned to the intervention group.
|
During the index emergency department visit (average 6 hours)
|
|
Time from emergency department presentation to final diagnosis
Tijdsspanne: During the index emergency department visit (average 6 hours)
|
Time required from emergency department presentation until establishment of the physician's final emergency department diagnosis.
|
During the index emergency department visit (average 6 hours)
|
|
Diagnostic reclassification after Generative Pre-trained Transformer (GPT)-assisted evaluation
Tijdsspanne: During the index emergency department visit (average 6 hours)
|
Frequency of changes between the physician's initial working diagnosis and the final emergency department diagnosis after review of Generative Pre-trained Transformer (GPT)-generated diagnostic recommendations.
|
During the index emergency department visit (average 6 hours)
|
|
Physician diagnostic confidence
Tijdsspanne: During the index emergency department visit (average 6 hours)
|
Physician-reported diagnostic confidence recorded before and after Generative Pre-trained Transformer (GPT)-assisted diagnostic support using the prespecified study assessment scale.
|
During the index emergency department visit (average 6 hours)
|
|
Physician acceptance of Generative Pre-trained Transformer (GPT)-generated diagnostic recommendations
Tijdsspanne: During the index emergency department visit (average 6 hours)
|
Frequency of physician acceptance, modification, or rejection of Generative Pre-trained Transformer (GPT)-generated diagnostic recommendations in the intervention group.
|
During the index emergency department visit (average 6 hours)
|
|
Emergency department disposition accuracy
Tijdsspanne: Up to hospital discharge (average 3 days)
|
Accuracy of emergency department disposition decisions, including discharge, hospital admission, or intensive care unit admission, compared with the adjudicated reference diagnosis.
|
Up to hospital discharge (average 3 days)
|
|
Emergency department length of stay
Tijdsspanne: Up to hospital discharge (average 3 days)
|
Length of stay in the emergency department measured from patient presentation until emergency department discharge or hospital admission.
|
Up to hospital discharge (average 3 days)
|
|
Hospital length of stay
Tijdsspanne: Up to hospital discharge (average 3 days)
|
Total duration of hospitalization from admission until hospital discharge.
|
Up to hospital discharge (average 3 days)
|
|
In-hospital mortality
Tijdsspanne: Up to hospital discharge (average 3 days)
|
All-cause mortality occurring during the index hospitalization.
|
Up to hospital discharge (average 3 days)
|
|
30-day all-cause mortality
Tijdsspanne: 30 days
|
All-cause mortality occurring within 30 days after the index emergency department visit.
|
30 days
|
|
30-day emergency department revisit
Tijdsspanne: 30 days
|
Revisit to any emergency department for any cause within 30 days after the index emergency department visit.
|
30 days
|
|
30-day hospital readmission
Tijdsspanne: 30 days
|
Hospital readmission for any cause within 30 days after discharge from the index hospitalization.
|
30 days
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019 Jan;25(1):44-56. doi: 10.1038/s41591-018-0300-7. Epub 2019 Jan 7.
- Lopez-Puerta JM, Fernandez-Marin MR, Martin Benlloch JA, Lorente R. Spinal osteoid osteoma recurring as an aggressive osteoblastoma. Neurocirugia (Engl Ed). 2020 May-Jun;31(3):146-150. doi: 10.1016/j.neucir.2019.06.002. Epub 2019 Sep 2. English, Spanish.
- ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):72. doi: 10.1038/s41572-020-0212-y. No abstract available.
- Kim TH, Kim CH, Choi SG. Radiation-induced angiosarcoma (RIAS) of the maxilla: a case report. J Korean Assoc Oral Maxillofac Surg. 2020 Aug 31;46(4):288-291. doi: 10.5125/jkaoms.2020.46.4.288.
- Li R, Chen X, Wang Y. Adverse events analysis of Relugolix (Orgovyx(R)) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS). PLoS One. 2024 Oct 22;19(10):e0312481. doi: 10.1371/journal.pone.0312481. eCollection 2024.
- Asravor RK. Uncovering the forgotten story of the impact of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome on economic growth in Ghana: A gender analysis. Int J Health Plann Manage. 2023 Sep;38(5):1495-1509. doi: 10.1002/hpm.3675. Epub 2023 Jun 23.
- Shakiba M, Nazemipour M, Mansournia N, Mansournia MA. Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial. Sci Rep. 2023 Apr 10;13(1):5833. doi: 10.1038/s41598-023-32855-3.
- Hsu HW, Chiu MC, Shoemaker D, Yang CS. Viral infections in fire ants lead to reduced foraging activity and dietary changes. Sci Rep. 2018 Sep 10;8(1):13498. doi: 10.1038/s41598-018-31969-3.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 januari 2027
Primaire voltooiing (Geschat)
31 december 2028
Studie voltooiing (Geschat)
31 december 2029
Studieregistratiedata
Eerst ingediend
18 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
21 juli 2026
Eerst geplaatst (Werkelijk)
27 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
27 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
21 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ER-VISION-AI study
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
ONBESLIST
Beschrijving IPD-plan
The investigators have not yet determined whether de-identified individual participant data (IPD), including the analyzable dataset and supporting documentation, will be shared with researchers outside the study team.
A final decision will be made after completion of the study, taking into consideration institutional policies, participant privacy, ethical requirements, and applicable regulations.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .